Farallon Capital Management LLC Reata Pharmaceuticals Inc Transaction History

Farallon Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $10 Million - $13.4 Million	126,700 Added 38.98%	451,700 $46.1 Million
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $215,950 - $652,190	-7,000 Reduced 2.11%	325,000 $29.5 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $7.35 Million - $14 Million	332,000 New	332,000 $12.6 Million
Q4 2019 Feb 13, 2020	SELL	$74.57 - $217.92 $7.98 Million - $23.3 Million	-107,060 Reduced 58.8%	75,000 $15.3 Million
Q3 2019 Nov 14, 2019	SELL	$71.26 - $95.75 $44 Million - $59.2 Million	-617,940 Reduced 77.24%	182,060 $14.6 Million
Q2 2019 Aug 14, 2019	BUY	$77.72 - $94.35 $3.89 Million - $4.72 Million	50,000 Added 6.67%	800,000 $75.5 Million
Q1 2019 May 15, 2019	BUY	$51.9 - $101.79 $2.6 Million - $5.09 Million	50,000 Added 7.14%	750,000 $64.1 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $1.29 Million - $2.03 Million	26,500 Added 3.93%	700,000 $39.3 Million
Q3 2018 Nov 14, 2018	BUY	$35.64 - $92.06 $24 Million - $62 Million	673,500 New	673,500 $55.1 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.